Skip to main content
Premium Trial:

Request an Annual Quote

Ingenuity, Eksigent Technologies, Amersham


Ingenuity of Mountain View, Calif., has released a new version of its Ingenuity Pathways Analysis software. The web-delivered application allows researchers to submit gene or protein lists to Ingenuity’s database in order to find functionally annotated biological networks. New features include the ability to overlay well-known metabolic and signaling pathways on generated networks; to expand out from a single network by clicking on a node; to explore the scientific evidence that underlies the networks in a dataset; to research known drug targets to discover therapeutic implications of data; and to discover and validate biomarkers.

Eksigent Technologies of Livermore, Calif., has modified its NanoLC-1D Proteomics nanoscale HPLC. The new version can rapidly inject samples, enabling researchers to load large samples onto trap or analytical columns. In addition, it has Thermo Electron’s Xcalibur software integrated.

Amersham announced last week the release of a pre-charged Ni Sepharose High Performance medium for the purification of His-tagged proteins by affinity chromatography. According to Amersham, the new bead matrix offers the highest binding capacity currently available.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.